Enovis Corporation

Fundamentals4.0
Price Action5.0
News Sentiment6.0
AI Rating
5.0

Key Drivers

  • Margin recovery
  • Debt burden
  • Thin liquidity

AI
AI Summary

5.0

ENOV should be viewed primarily as a balance-sheet repair and execution-recovery play rather than a clean growth story, with upside now hinging on whether its recent margin and operating-profit improvement can persist long enough to generate consistent free cash flow and reduce debt before leverage and thin cash reassert pressure.

MarginExpansion
Leverage
Turnaround‍

Price Chart

Loading chart...

Financial Metrics

-
Revenue (TTM)
-
Net Income (TTM)
-
EPS (Q)
-
MCAP

Deep Analysis

Research tool. Not personalized advice.

Fundamental Analysis

4.0

Key Financial Insights:

  • Margin recovery
  • Debt burden
  • Thin liquidity

ENOV is showing a meaningful quarterly turnaround with better margins and cash flow, but heavy leverage, thin cash, and large annual losses keep the risk profile elevated.

turnaround
leverage

Price Behavior

5.0
Research tool. Not personalized advice. Technical analysis is for informational purposes only.

Key Price Behavior Insights:

  • Support defense
  • Lower highs
  • Overhead resistance

ENOV's rebound from $20.04 to $22.50 suggests buyers are defending $20-$21, but the last month remains choppy with lower highs and overhead resistance at $22.70-$24.00 limiting a bullish confirmation.

ENOV
watchlist
Support Level: $20.00-$21.00
Resistance Level: $22.70-$24.00

Sharp rebound from $20.04 to $22.50 after a quick pullback

Sentiment & News

6.0

Key News Insights:

  • Pediatric brace launch
  • Compliance-focused design
  • Growth-stock visibility

ENOV is gaining traction from its first-of-its-kind pediatric scoliosis brace launch and renewed visibility as a growth-stock name under $100.

Innovation
Growth

The news is mildly positive for ENOV, signaling product innovation that could support clinical adoption while also reinforcing investor interest in the stock